Project Grant R03CA293119
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $168K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- The National Cancer Institute (NCI) awarded a $721,723 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Beckman Research Institute of the City of Hope. The grant supports research to understand the biological mechanisms driving the transition from chronic lymphocytic leukemia (CLL) to the more aggressive Richter's transformation (RT), a devastating complication with poor prognosis. Key objectives include determining how the MGA/MYC/NME1 regulatory axis impacts tumor...
- The National Cancer Institute (CFDA 93.396 Cancer Biology Research) awarded a $477,218 Project Grant to Northwestern University to study the persistence of leukemia stem cells during tyrosine kinase inhibitor treatment in chronic myeloid leukemia (CML). The research aims to understand the mechanisms behind the emergence of quiescent and proliferative leukemia stem cell subsets, and their interaction with ABT cells, which influences the duration of therapy-free remission in CML patients. The...
- This federal Project Grant award of $714,110.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research by New York University School of Medicine to translate insights in follicular lymphoma for improved diagnosis and classification. The research aims to identify reliable predictive biomarkers to guide frontline risk stratification and treatment for high-risk follicular lymphoma patients, who face a poor prognosis due to early disease...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...
- The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
- The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $530,106 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, awarded on September 11, 2025, supports research aimed at understanding and targeting polyamine metabolism in leukemia stem cells (LSCs) to improve outcomes for patients with acute myeloid leukemia (AML). The overarching goal is to develop LSC-directed therapies that can help overcome...
- The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...
- This $702,495 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope in California aims to develop innovative approaches for treating T-cell lymphomas (TCLs). The research will focus on targeting tumor-associated macrophages (TAMs) in the tumor microenvironment by inhibiting the CaMK2 kinase, which has been shown to play a pivotal role in TCL development. The research team will explore how...